---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-25-000007"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:14:29.481056+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# aTyr completes Phase 3 EFZO-FIT last patient visit; topline data mid-September 2025

## Summary
- Last patient visit completed in Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis; topline data expected mid-September 2025.
- Cash, equivalents and investments were $83.2M at June 30, 2025; raised ~$30.7M from ATM offering post-quarter.
- R&D expenses $15.4M, G&A $4.9M for Q2 2025.
- Interim Phase 2 EFZO-CONNECT data in SSc-ILD showed stable/improved mRSS in efzofitimod-treated patients (n=8).
- Advanced ATYR0101 to IND candidate for pulmonary fibrosis; IND filing expected H2 2026.

## SEC filing metadata
- accession: 0001339970-25-000007
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/0001339970-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/atyr-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-25-000007
- JSON: https://secwatch.observer/filing/0001339970-25-000007.json
- Plain text: https://secwatch.observer/filing/0001339970-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.